The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015:648108. [Comprehensive mechanism review; topical and systemic mechanisms; the primary Pickart review paper.]
Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 19(7):1987. [Gene expression data from Broad Institute connectivity map; 1,500+ genes modulated; key paper for systemic gene regulation rationale.]
Arul V, Kartha R, Jayakumar R. (2007). A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sciences. 80(4):275-84. [Animal wound healing model; GHK-Cu systemic effects; key reference for the remote-site healing signal.]
Ward WA, et al. (2023). Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv preprint. [Intranasal route animal study; cognitive aging; neuroinflammation reduction; relevant to non-topical route pharmacology in preclinical models.]
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 238(2):343-6. [Foundational fibroblast collagen synthesis data; in vitro; mechanistic basis.]
Anela Protocol. Originator: 'Anela' on r/peptides and related community forums (~2018-2020). Community protocol documentation covering reconstitution (50mg/3mL BAC), dose escalation (1mg days 1-15; 2mg days 16-30), 30-day cycle, ISR management, and stacking guidance. [Community source — not peer-reviewed; the canonical injectable GHK-Cu protocol document as documented in community threads and protocol repositories.]
The injectable GHK-Cu community is running a protocol without a single published human RCT to validate it. This is the most important sentence in this chapter. Everything that follows is either animal evidence, mechanistic extrapolation, or community-documented experience.
GHK-Cu injectable use has grown substantially since 2019. The compound is accessible from peptide research vendors, reconstitution is straightforward, and the topical evidence is compelling enough that many users reason 'if it works on the skin surface, systemic injection should work even better.' This reasoning is not unreasonable — but it is an extrapolation, not a proven step. The pharmacology of a topically applied compound that works primarily through local dermal fibroblast signaling is different from the pharmacology of the same compound delivered systemically at concentrations that circulate through the entire body.
The 461-paragraph combined GHK-Cu chapter in The Peptide Bible previously documented both routes together, which is how community discussion typically frames it. The route split creates two honest chapters: one with 8+ human RCTs (topical, Grade B) and this one with zero human RCTs (injectable, Grade C — based on animal evidence for systemic healing effects). The split exists to prevent topical evidence from being cited as validation for injectable protocols. It is not.
THE CENTRAL TENSION
The community has created one of the most thoughtfully documented peptide protocols in this book — the Anela Protocol has specific reconstitution mathematics, ISR-reduction dilution standards, dose escalation logic, and cycle lengths. This community infrastructure exists despite the absence of a single human RCT for the injectable route. The central tension: is the systemic healing signal from animal studies (injected GHK-Cu healing remote wounds) sufficient to justify the extrapolation to human injectable protocols? The animal evidence is consistent and across multiple species. The mechanistic pharmacology is coherent. The topical human evidence is robust. And the specific injectable route in humans has not been validated by a single controlled trial. This chapter documents the protocol honestly, explains the evidence for each element, and lets readers make informed decisions.
The Anela Protocol is the community's most widely adopted injectable GHK-Cu protocol. It defines reconstitution, dosing, site, cycle, and ISR management. Every element is documented here with honest evidence framing.
Named after its originator 'Anela' on the r/peptides community forums, this protocol emerged from community experimentation and has been refined by thousands of user cycles since approximately 2018-2020. It is not a clinical protocol. It has no RCT validation. It is the most thoroughly documented community consensus protocol for injectable GHK-Cu and is reproduced here in full.
Protocol Element
Standard
Evidence Basis
Vial
50 mg lyophilized GHK-Cu
Standard vendor vial size; all protocol mathematics based on this
Reconstitution
3 mL bacteriostatic water (BAC water)
Community ISR-reduction standard; ~16.7 mg/mL concentration
Phase 1 dose (Days 1-15)
1 mg/day SubQ
Community standard start dose; allows tolerance assessment; no human trial data
Phase 2 dose (Days 16-30)
2 mg/day SubQ
Dose escalation after tolerance confirmed; no human PK/PD data for this escalation
Injection route
Subcutaneous (SubQ); insulin syringe
Extrapolated from animal SubQ studies; IM less common but used
Injection site
Abdomen (preferred); thigh; upper arm
Rotate with each injection to prevent ISR site accumulation
Injection time
Before bed (evening)
No pharmacological rationale specific to GHK-Cu; mirrors growth hormone secretagogue protocols; community convention
Cycle length
30 days active
Community standard; no pharmacological basis for cycle length established in humans
Rest period
Minimum 30 days off between cycles
Copper accumulation concern; no clinical data on washout; community-derived
ISR management
Proper dilution (3mL/50mg); slow injection; ice application before; rotation
Community-validated techniques; no ISR trial data for GHK-Cu specifically
Stacking
BPC-157 and/or TB-500 (GLOW stack); also used as standalone
See GLOW Stack chapter for combined protocol
The scientific case for injectable GHK-Cu rests on a specific animal finding: GHK-Cu injected at a distant site from a wound improves healing at the wound site. This systemic signal is not achievable by topical application.
Topical GHK-Cu, even with advanced delivery systems, acts primarily at the site of application. The clinical evidence (Leyden trials, Yuvan 2023) shows skin changes at the application site. Animal models, however, revealed something different about injected GHK-Cu: a systemic enhancement of healing that operates through circulating levels of the peptide. In studies where GHK-Cu was injected into rat thigh muscles, wound healing at ear and other remote sites was significantly improved — with increased collagen production, angiogenesis, and wound closure at locations far from the injection site. This is a pharmacologically meaningful distinction: the injectable route is not simply a more efficient way to deliver GHK-Cu to local tissue — it is a route capable of producing systemic effects that topical delivery cannot.
The proposed mechanism: injected GHK-Cu raises circulating plasma levels of the peptide, restoring the age-related decline in GHK-Cu that Pickart documented (200 ng/mL at age 20 → 80 ng/mL at age 60). Elevated circulating GHK-Cu then interacts with tissue-resident cells throughout the body — fibroblasts in joints, ligaments, skin at non-application sites, and potentially neural tissue. If this restoration mechanism is real and translates to humans, injectable GHK-Cu would offer systemic tissue signaling that no topical product can match. This remains Grade C (animal) — not validated in humans. But it is the scientific rationale that makes the injectable route plausible and different from simply injecting a topical compound.
Additional injectable-specific rationale: GHK-Cu is a peptide and is not orally bioavailable (broken down by GI peptidases). Topical delivery is formulation-limited. Injectable SubQ delivery provides the most controlled and reliable systemic bioavailability of GHK-Cu of any route currently accessible to community users. The intranasal route has been studied in animal models (intranasal GHK in aging mice showed cognitive benefits in a 2023 preprint) but is not yet established as a community protocol.
Published human evidence specifically evaluating subcutaneous or intramuscular injectable GHK-Cu: zero RCTs. Two observational reports exist in the literature — case reports or clinical observations from practitioners using GHK-Cu injections — but these are not controlled and not peer-reviewed in a systematic way. The evidence grade for injectable GHK-Cu as a route is D-E: mechanistic extrapolation and community observational data. This is not nothing — the mechanistic pharmacology is well established. But it is not clinical proof of efficacy or safety for systemic injectable administration.
Multiple animal studies across rats, mice, and pigs demonstrate that systemically administered GHK-Cu produces healing enhancement at remote wound sites. The key parameters established in animal models: effective dose range is picomolar to nanomolar in tissue; collagen production, angiogenesis, and wound closure are all significantly improved; the effect is dose-dependent within a therapeutic range; effects persist beyond the acute administration period, consistent with gene expression changes rather than simple receptor occupation. These studies establish biological plausibility for systemic GHK-Cu delivery and provide the scientific foundation for the community injectable protocol. Grade C: animal models across multiple species; consistent findings; not validated in human controlled trials for the injectable route.
Evidence Type
Grade
Finding
Route
8+ human RCTs (Leyden, Abdulghani, Yuvan)
B
Collagen density +28%; wrinkle reduction 55-67%; skin thickness increase; outperforms Vitamin C and retinoic acid
Topical — not applicable to injectable claims
Animal systemic healing studies (rat/mouse/pig)
C
Remote site wound healing improved when GHK-Cu injected distally; collagen, angiogenesis, wound closure all enhanced
Systemic injection — extrapolated to SubQ human use
In vitro fibroblast studies (Maquart 2015)
D
Collagen/elastin synthesis stimulated at 0.01-100 nM; MMP/TIMP balance regulated
Cell culture — mechanistic basis, not clinical proof
Intranasal mouse study (2023 preprint, Ward et al.)
C
Intranasal GHK reduced cognitive decline in aging mice; neuroinflammation markers improved
Intranasal animal — different route, relevant to CNS applications
Community observational data (Anela Protocol)
E
Widely reported: healing acceleration, improved skin quality, wellbeing; ISR as primary adverse effect
SubQ human — community consensus, no controls, no blinding
Human injectable controlled trial
No grade — does not exist
Not published as of mid-2026
SubQ/IM — no trial exists
Injectable GHK-Cu comes as a lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water (BAC water). The dilution choice determines dose volume, concentration per injection, and critically, ISR severity.
Community GHK-Cu vials are typically available in 50 mg configurations (less commonly 25 mg or 100 mg). The 50 mg vial is the standard around which community protocols are built.
Vial Size
BAC Water Added
Final Concentration
Dose Volume for 1 mg
Notes
50 mg
2 mL
25 mg/mL (25,000 mcg/mL)
40 mcL (0.04 mL)
High concentration; more ISR; not the Anela standard
50 mg
3 mL (Anela standard)
16.7 mg/mL (~16,700 mcg/mL)
60 mcL (0.06 mL)
ISR-optimized dilution; community standard; ~65% less ISR than 2mL reconstitution
50 mg
4 mL
12.5 mg/mL (12,500 mcg/mL)
80 mcL (0.08 mL)
Further dilution; even less ISR; easier to draw on insulin syringe
50 mg
10 mL
5 mg/mL (5,000 mcg/mL)
200 mcL (0.2 mL)
Maximum dilution; lowest ISR; larger injection volume; some users prefer
WHY 3mL/50mg IS THE ANELA PROTOCOL STANDARD
The 3mL/50mg reconstitution is specifically chosen to balance two competing factors: (1) sufficient concentration for a conveniently small injection volume on an insulin syringe, and (2) dilute enough to substantially reduce injection site reactions (ISR). At 25 mg/mL (2mL reconstitution), the copper ion concentration per injection is high enough that many users experience significant localized burning, redness, and nodule formation at the injection site — the ISR problem. At 16.7 mg/mL (3mL reconstitution), the same 1 mg dose is delivered in a larger volume with lower peak copper concentration per mL, reducing ISR by an estimated ~65% in community experience. This is empirically derived community knowledge — no published trial has compared ISR rates across dilution schemes for GHK-Cu specifically. But the physics are sound: lower copper concentration per mL produces less local copper ion irritation.
Community users draw GHK-Cu using U-100 insulin syringes (100 units = 1 mL). With the 3mL/50mg reconstitution (16.7 mg/mL): 1 mg dose = 0.06 mL = 6 units on a U-100 syringe. 2 mg dose = 0.12 mL = 12 units. With 4mL/50mg (12.5 mg/mL): 1 mg = 8 units; 2 mg = 16 units. These numbers should be memorized or written next to the vial before each injection session. Calculation errors with concentrated peptide solutions are one of the most common injectable protocol mistakes.
ISR is the primary adverse effect of injectable GHK-Cu and the main practical reason most community protocols spend significant effort on dilution and technique.
Injection site reactions with GHK-Cu occur primarily because of the copper ion (Cu²⁺) in the complex. When injected subcutaneously at higher concentrations, the copper produces local inflammation in the SubQ tissue — the biological equivalent of introducing a metal ion into tissue that wasn't expecting it. Symptoms: burning or stinging sensation immediately post-injection (seconds to minutes); localized redness and warmth (hours); small subcutaneous nodule or lump at injection site (days to weeks); occasionally mild bruising. Most ISR is transient and resolves within days. Persistent nodules that do not resolve within 2 weeks, expanding erythema, fever, or systemic symptoms warrant medical evaluation — these are not expected ISR but may indicate local infection.
GHK-Cu delivers copper to tissue with each injection. At daily therapeutic doses over long cycles, the cumulative copper load deserves explicit attention.
Each GHK molecule carries one Cu²⁺ ion. The atomic weight of copper is approximately 63.5 g/mol; GHK-Cu's molecular weight is approximately 408 Da. At a 1 mg/day dose of GHK-Cu: the copper content is approximately 0.155 mg/day (63.5/408 × 1 mg). At a 2 mg/day dose: approximately 0.31 mg/day copper. For context: the RDA for dietary copper is 0.9 mg/day; upper tolerable intake is 10 mg/day. A 30-day cycle at 2 mg/day adds approximately 9.3 mg copper from GHK-Cu — below the UL but adding meaningfully to dietary copper. A 16-week continuous daily protocol at 2 mg/day delivers approximately 34 mg copper from GHK-Cu alone.
The copper concern has two dimensions: (1) Wilson disease (autosomal recessive copper metabolism disorder — ATP7B gene mutation) prevents normal copper excretion; GHK-Cu is absolutely contraindicated. (2) In healthy individuals without Wilson disease, copper is primarily excreted via bile through the liver. Long protocols in people with subclinical liver stress or elevated baseline copper may cause accumulation. Serum copper and ceruloplasmin monitoring before and during long cycles is the appropriate mitigation for any protocol extending beyond 8 weeks.
COPPER ACCUMULATION MONITORING RECOMMENDATION
For any GHK-Cu injectable protocol exceeding 8 weeks or running multiple consecutive cycles without adequate rest: baseline serum copper and ceruloplasmin before starting; recheck at 8-week mark. Normal serum copper: 70-140 mcg/dL for women; 70-140 mcg/dL for men. Ceruloplasmin (the primary copper transport protein): 15-35 mg/dL. Values trending upward across multiple cycle measurements suggest accumulation — pause the protocol and consult a physician. This monitoring recommendation is derived from copper toxicology principles, not from a GHK-Cu-specific clinical study — because no such study exists.
Adjust any input. The syringe draw updates live. Tap a preset row to load that dilution.
| BAC | Concentration | Per unit | Notes |
|---|---|---|---|
| 2 mL | 25 mcg/mL | 40 mcg | High concentration; more ISR; not the Anela standard |
| 3 mL | 16.7 mcg/mL | 60 mcg | ISR-optimized dilution; community standard; ~65% less ISR than 2mL reconstitution |
| 4 mL | 12.5 mcg/mL | 80 mcg | Further dilution; even less ISR; easier to draw on insulin syringe |
| 10 mL | 5 mcg/mL | 200 mcg | Maximum dilution; lowest ISR; larger injection volume; some users prefer |
GHK-Cu's pharmacokinetics after subcutaneous injection in humans have not been formally characterized. What is known from related data: the plasma half-life of GHK peptide is very short in vitro (minutes). The GHK-Cu complex may have longer tissue-resident activity than plasma half-life suggests, because copper binding to tissue proteins provides a depot effect. Animal pharmacokinetic data suggests rapid systemic distribution after SubQ injection followed by tissue uptake. The specific Tmax, Cmax, and half-life in humans after SubQ injection at community doses are unknown. This means there is no pharmacokinetic basis for choosing once-daily versus twice-daily dosing in humans — the community convention (once daily before bed) is not pharmacokinetically derived. It is a practical convention borrowed from sleep-timing peptide protocols.
GHK-Cu injectable is most commonly used in community protocols as part of the GLOW stack (GHK-Cu + BPC-157 + TB-500). Each compound contributes a different dimension: BPC-157 handles local structural repair and gut protection; TB-500 promotes systemic healing via actin regulation; GHK-Cu adds the copper-mediated collagen remodeling and gene expression layer. The combination is coherent mechanistically — these are complementary rather than redundant mechanisms. See the GLOW Stack chapter for the complete combined protocol, timing, dose ratios, and stacking-specific evidence grade.
GHK-Cu injectable is also used as a standalone protocol — particularly for community users whose primary goal is systemic collagen support, skin quality, or healing in contexts where BPC-157 or TB-500 are not indicated. The standalone protocol uses the Anela Protocol as documented in Section 5.
The topical human RCTs establish that GHK-Cu applied to skin produces measurable skin improvement. They do not establish that subcutaneous injection produces equivalent or superior systemic effects. The evidence grade for injectable GHK-Cu (Grade C — animal) is lower than for topical (Grade B — human RCT). Using topical evidence to validate injectable protocols is incorrect evidence attribution.
GHK is endogenous; exogenous supplementation at doses well above endogenous plasma levels (80-200 ng/mL naturally versus micrograms to milligrams injected) is a pharmacological intervention, not simple restoration. At concentrations significantly above physiological range, effects may differ from those observed at physiological concentrations. GHK-Cu's angiogenic activity is particularly relevant here — the active malignancy contraindication applies even though GHK is a natural compound.
GHK-Cu is effective at nanomolar concentrations. Copper toxicity at high concentrations is well established. More copper delivery does not mean more collagen synthesis — the dose-response for GHK-Cu shows a bell-curve or plateau at higher concentrations in cell culture. The therapeutic window is narrow at the tissue level; more injected dose does not proportionally increase benefit and may introduce copper accumulation risk without additional collagen stimulation benefit.
Copper accumulation risk increases with continuous long-term dosing. The community convention of 30 days on/30 days off is a practical harm-reduction practice derived from copper toxicology logic — though not validated in a human GHK-Cu trial. Continuous year-round injectable copper delivery without rest periods and without monitoring is not supported by evidence and is inconsistent with responsible use of any copper-delivering compound.
ACTIVE MALIGNANCY — HARD STOP
Active cancer or suspected malignancy is an absolute contraindication for injectable GHK-Cu. GHK-Cu's systemic angiogenic activity (VEGF upregulation, promotion of new blood vessel formation) could support tumor vascularization. This is not a theoretical consideration to be 'weighed against benefits' — it is a hard stop. Do not use injectable GHK-Cu with active cancer. This applies regardless of tumor type, stage, or size. For anyone with cancer history in remission: physician consultation before starting any GHK-Cu protocol.
Wilson disease (ATP7B gene mutation; hereditary copper accumulation) is an absolute contraindication for GHK-Cu by any route. The copper delivery mechanism that makes GHK-Cu pharmacologically interesting is harmful in the context of impaired copper metabolism. Any patient with documented or suspected Wilson disease must not use GHK-Cu.
GHK-Cu's angiogenic activity and gene expression effects have not been evaluated in pregnancy or lactation. Animal studies show that copper metabolism is critical in fetal development. Injectable GHK-Cu during pregnancy or breastfeeding is not recommended without explicit physician oversight.
Test
Timing
Purpose
Serum copper
Before starting; every 8 weeks on protocol
Accumulation monitoring; baseline reference
Ceruloplasmin
Before starting; every 8 weeks on protocol
Copper transport protein; accumulation indicator
Liver function panel (ALT/AST)
Before starting; at cycle end
Copper is hepatically cleared; baseline liver function reference
Injection site assessment
Every injection
Active ISR monitoring; nodules >2 weeks not resolving → stop and evaluate
Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015:648108. [Comprehensive mechanism review; topical and systemic mechanisms; the primary Pickart review paper.]
Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 19(7):1987. [Gene expression data from Broad Institute connectivity map; 1,500+ genes modulated; key paper for systemic gene regulation rationale.]
Arul V, Kartha R, Jayakumar R. (2007). A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sciences. 80(4):275-84. [Animal wound healing model; GHK-Cu systemic effects; key reference for the remote-site healing signal.]
Ward WA, et al. (2023). Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv preprint. [Intranasal route animal study; cognitive aging; neuroinflammation reduction; relevant to non-topical route pharmacology in preclinical models.]
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 238(2):343-6. [Foundational fibroblast collagen synthesis data; in vitro; mechanistic basis.]
Anela Protocol. Originator: 'Anela' on r/peptides and related community forums (~2018-2020). Community protocol documentation covering reconstitution (50mg/3mL BAC), dose escalation (1mg days 1-15; 2mg days 16-30), 30-day cycle, ISR management, and stacking guidance. [Community source — not peer-reviewed; the canonical injectable GHK-Cu protocol document as documented in community threads and protocol repositories.]
Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015:648108. [Comprehensive mechanism review; topical and systemic mechanisms; the primary Pickart review paper.]
Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 19(7):1987. [Gene expression data from Broad Institute connectivity map; 1,500+ genes modulated; key paper for systemic gene regulation rationale.]
Arul V, Kartha R, Jayakumar R. (2007). A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sciences. 80(4):275-84. [Animal wound healing model; GHK-Cu systemic effects; key reference for the remote-site healing signal.]
Ward WA, et al. (2023). Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv preprint. [Intranasal route animal study; cognitive aging; neuroinflammation reduction; relevant to non-topical route pharmacology in preclinical models.]
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 238(2):343-6. [Foundational fibroblast collagen synthesis data; in vitro; mechanistic basis.]
Anela Protocol. Originator: 'Anela' on r/peptides and related community forums (~2018-2020). Community protocol documentation covering reconstitution (50mg/3mL BAC), dose escalation (1mg days 1-15; 2mg days 16-30), 30-day cycle, ISR management, and stacking guidance. [Community source — not peer-reviewed; the canonical injectable GHK-Cu protocol document as documented in community threads and protocol repositories.]
Injectable GHK-Cu is a pharmacologically coherent extrapolation from robust animal data and topical human evidence. It is not validated for this route in humans. The community has created a thoughtful protocol in the absence of that validation. Use it with honest risk framing.
The honest summary: the injectable GHK-Cu community has done something sophisticated — built a protocol (the Anela Protocol) with specific dilution mathematics for ISR reduction, a dose escalation approach, a cycle length, and monitoring conventions. This infrastructure exists not because there is human RCT evidence, but because the animal evidence for systemic healing effects is persuasive and the topical human evidence demonstrates the mechanism is real. For users who understand what they are extrapolating from and toward, and who implement the protocol with appropriate monitoring (copper, liver function, ISR assessment), injectable GHK-Cu represents a reasonable approach to accessing systemic GHK-Cu biology. The active malignancy hard stop is non-negotiable. The Wilson disease contraindication is absolute. The copper accumulation risk on long protocols is real and requires monitoring.
— End of GHK-Cu (Injectable) —
THE PEPTIDE BIBLE | GHK-Cu (Injectable) | For Research & Educational Purposes Only
GHK-Cu (Injectable): Glycyl-L-Histidyl-L-Lysine-Cu²⁺; MW ~408 Da; subcutaneous or intramuscular injection. STUDY COUNTS: humanRct: 0, humanObs: 2, animal: 45, inVitro: 60. EVIDENCE GRADE: C — animal replicated for systemic healing; E — community consensus for specific injectable protocols. ZERO PUBLISHED HUMAN RCTs FOR INJECTABLE ROUTE as of mid-2026. ALL TOPICAL EVIDENCE IS SEPARATE — see GHK-Cu (Topical). THE SYSTEMIC HEALING SIGNAL (Grade C): injected GHK-Cu improves wound healing at remote sites from injection in rat, mouse, pig models; collagen, angiogenesis, wound closure all enhanced; basis for injectable route rationale. MECHANISM: same as topical (TGF-beta collagen, MMP/TIMP, integrin, gene expression) but systemic rather than local; copper delivered to all tissues not just skin surface. ANELA PROTOCOL: 50 mg vial; 3 mL BAC water reconstitution (16.7 mg/mL) — ISR-optimized dilution; 1 mg/day SubQ days 1-15; 2 mg/day days 16-30; 30-day cycle; 30-day rest minimum; abdomen preferred; site rotation mandatory; insulin syringe. ISR: primary adverse effect; copper ion irritation; managed by 3mL dilution (~65% ISR reduction vs 2mL), slow injection, pre-injection ice, site rotation. RECONSTITUTION MATH (3mL/50mg): 1 mg = 60 mcL = 6 units on U-100 syringe; 2 mg = 12 units. COPPER ACCUMULATION: each 1 mg GHK-Cu delivers ~0.155 mg Cu²⁺; at 2 mg/day × 30 days = ~9.3 mg copper from GHK-Cu alone (below 10 mg/day UL but cumulative); long protocols require copper/ceruloplasmin monitoring. PHARMACOKINETICS: uncharacterized in humans after SubQ injection; very short plasma half-life (minutes) but tissue depot effect likely via copper-protein binding; once-daily dosing is community convention, not pharmacokinetically derived. ACTIVE MALIGNANCY: hard stop — VEGF angiogenic activity could support tumor vascularization; no exceptions. WILSON DISEASE: absolute contraindication (ATP7B mutation; impaired copper excretion). STACKING: used in GLOW Stack with BPC-157 + TB-500 (see GLOW Stack chapter). MONITORING: serum copper + ceruloplasmin at baseline and q8 weeks; liver panel (ALT/AST) before starting; ISR assessment every injection. COMPANION CHAPTER: GHK-Cu (Topical) for 8+ human RCTs, formulation guidance, Leyden trials, Yuvan 2023 dermal ultrasound data.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.